Jazz Pharmaceuticals price target raised to $235 from $210 at Needham

Needham analyst Ami Fadia raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $235 from $210 and keeps a Buy rating on the shares. The firm cites the company having presented the HERIZON-GEA-01 study with additional color on the subgroup analysis, noting that the overall data favored zani treatment arms across all subgroups with a longer tail on PFS for tislelizumab arm and slightly higher efficacy in TAP under 1% over TAPat 1% or higher. A key opinion leader on the call also noted that the benefit demonstrated by zani is “practice-changing” and anticipates zanidatamab plus chemo tislelizumab will quickly replace the current standard of care, the analyst tells investors in a research note.